Immunic AG is a young biotech company based in the Munich/Germany biotech hub Martinsried that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis. The company focuses its research & development efforts on orally available, small molecule inhibitors.

The mission of Immunic AG is to develop innovative immune modulators (in particular those that block TH17- and TH1-mediated immune and autoimmune responses) and bring these drug candidates to clinical proof of concept in patients.

Immunic has currently two ongoing development programs:

• IMU-838 (an inhibitor of DHODH) for development in IBD: Starting Phase 2
• IMU-366/935 (an inhibitor of RORγt) relevant to a range of disease: Preclinical

For further information, please also contact our web site: http://www.immunic-therapeutics.com/